Gastric Cancer - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 610 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Gastric Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Gastric Cancer - Pipeline Review, H2 2014', provides an overview of the Gastric Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastric Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gastric Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gastric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastric Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
Introduction 7
Gastric Cancer Overview 8
Therapeutics Development 9
Gastric Cancer - Therapeutics under Development by Companies 11
Gastric Cancer - Therapeutics under Investigation by Universities/Institutes 20
Gastric Cancer - Pipeline Products Glance 22
Gastric Cancer - Products under Development by Companies 26
Gastric Cancer - Products under Investigation by Universities/Institutes 38
Gastric Cancer - Companies Involved in Therapeutics Development 39
Gastric Cancer - Therapeutics Assessment 141
Drug Profiles 161
Gastric Cancer - Recent Pipeline Updates 445
Gastric Cancer - Dormant Projects 573
Gastric Cancer - Discontinued Products 580
Gastric Cancer - Product Development Milestones 582
Appendix 590

List of Tables
Number of Products under Development for Gastric Cancer, H2 2014 28
Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2014 29
Number of Products under Development by Companies, H2 2014 31
Number of Products under Development by Companies, H2 2014 (Contd..1) 32
Number of Products under Development by Companies, H2 2014 (Contd..2) 33
Number of Products under Development by Companies, H2 2014 (Contd..3) 34
Number of Products under Development by Companies, H2 2014 (Contd..4) 35
Number of Products under Development by Companies, H2 2014 (Contd..5) 36
Number of Products under Development by Companies, H2 2014 (Contd..6) 37
Number of Products under Development by Companies, H2 2014 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H2 2014 40
Comparative Analysis by Late Stage Development, H2 2014 41
Comparative Analysis by Clinical Stage Development, H2 2014 42
Comparative Analysis by Early Stage Development, H2 2014 43
Comparative Analysis by Unknown Stage Development, H2 2014 44
Products under Development by Companies, H2 2014 45
Products under Development by Companies, H2 2014 (Contd..1) 46
Products under Development by Companies, H2 2014 (Contd..2) 47
Products under Development by Companies, H2 2014 (Contd..3) 48
Products under Development by Companies, H2 2014 (Contd..4) 49
Products under Development by Companies, H2 2014 (Contd..5) 50
Products under Development by Companies, H2 2014 (Contd..6) 51
Products under Development by Companies, H2 2014 (Contd..7) 52
Products under Development by Companies, H2 2014 (Contd..8) 53
Products under Development by Companies, H2 2014 (Contd..9) 54
Products under Development by Companies, H2 2014 (Contd..10) 55
Products under Development by Companies, H2 2014 (Contd..11) 56
Products under Investigation by Universities/Institutes, H2 2014 57
Gastric Cancer - Pipeline by AB Science, H2 2014 58
Gastric Cancer - Pipeline by AbbVie Inc., H2 2014 59
Gastric Cancer - Pipeline by AbGenomics International, Inc., H2 2014 60
Gastric Cancer - Pipeline by Advaxis, Inc., H2 2014 61
Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 62
Gastric Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 63
Gastric Cancer - Pipeline by Ambrx, Inc., H2 2014 64
Gastric Cancer - Pipeline by Amgen Inc., H2 2014 65
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2014 66
Gastric Cancer - Pipeline by Astellas Pharma Inc., H2 2014 67
Gastric Cancer - Pipeline by AstraZeneca PLC, H2 2014 68
Gastric Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 69
Gastric Cancer - Pipeline by Avipep Pty Ltd, H2 2014 70
Gastric Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 71
Gastric Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2014 72
Gastric Cancer - Pipeline by Bayer AG, H2 2014 73
Gastric Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 74
Gastric Cancer - Pipeline by Biotecnol, Inc., H2 2014 75
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 76
Gastric Cancer - Pipeline by Boston Biomedical, Inc., H2 2014 77
Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 78
Gastric Cancer - Pipeline by Celgene Corporation, H2 2014 79
Gastric Cancer - Pipeline by Celltrion, Inc., H2 2014 80
Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2014 81
Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 82
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2014 83
Gastric Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 84
Gastric Cancer - Pipeline by Covagen AG, H2 2014 85
Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H2 2014 86
Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 87
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 88
Gastric Cancer - Pipeline by DiaMedica Inc., H2 2014 89
Gastric Cancer - Pipeline by Dong-A Socio Group, H2 2014 90
Gastric Cancer - Pipeline by Eddingpharm, H2 2014 91
Gastric Cancer - Pipeline by Eli Lilly and Company, H2 2014 92
Gastric Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 93
Gastric Cancer - Pipeline by Erytech Pharma SA, H2 2014 94
Gastric Cancer - Pipeline by F-star Alpha Ltd., H2 2014 95
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 96
Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2014 97
Gastric Cancer - Pipeline by Galaxy Biotech, LLC, H2 2014 98
Gastric Cancer - Pipeline by Galena Biopharma, Inc., H2 2014 99
Gastric Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2014 100
Gastric Cancer - Pipeline by Genentech, Inc., H2 2014 101
Gastric Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 102
Gastric Cancer - Pipeline by GlycoNex Inc., H2 2014 103
Gastric Cancer - Pipeline by Glycotope GmbH, H2 2014 104
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 105
Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H2 2014 106
Gastric Cancer - Pipeline by ImmunoGen, Inc., H2 2014 107
Gastric Cancer - Pipeline by Immunomedics, Inc., H2 2014 108
Gastric Cancer - Pipeline by Imugene Limited, H2 2014 109
Gastric Cancer - Pipeline by Incuron, LLC, H2 2014 110
Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2014 111
Gastric Cancer - Pipeline by Intezyne, Inc, H2 2014 112
Gastric Cancer - Pipeline by ISU ABXIS Co.,Ltd., H2 2014 113
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2014 114
Gastric Cancer - Pipeline by Kadmon Corporation, LLC, H2 2014 115
Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 116
Gastric Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 117
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2014 118
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 119
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2014 120
Gastric Cancer - Pipeline by MacroGenics, Inc., H2 2014 121
Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2014 122
Gastric Cancer - Pipeline by Merck & Co., Inc., H2 2014 123
Gastric Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 124
Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2014 125
Gastric Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 126
Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2014 127
Gastric Cancer - Pipeline by MSM Protein Technologies, Inc., H2 2014 128
Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2014 129
Gastric Cancer - Pipeline by NeoPharm Co., Ltd., H2 2014 130
Gastric Cancer - Pipeline by Neopharm Ltd., H2 2014 131
Gastric Cancer - Pipeline by New Medical Enzymes AG, H2 2014 132
Gastric Cancer - Pipeline by Novartis AG, H2 2014 133
Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 134
Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H2 2014 135
Gastric Cancer - Pipeline by Oncothyreon Inc., H2 2014 136
Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 137
Gastric Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2014 138
Gastric Cancer - Pipeline by Panacea Biotec Limited, H2 2014 139
Gastric Cancer - Pipeline by Patrys Limited, H2 2014 140
Gastric Cancer - Pipeline by Pfizer Inc., H2 2014 141
Gastric Cancer - Pipeline by Pharmacyclics, Inc., H2 2014 142
Gastric Cancer - Pipeline by Priaxon AG, H2 2014 143
Gastric Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 144
Gastric Cancer - Pipeline by Regulon Inc., H2 2014 145
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 146
Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H2 2014 147
Gastric Cancer - Pipeline by Sanofi, H2 2014 148
Gastric Cancer - Pipeline by Sareum Holdings plc, H2 2014 149
Gastric Cancer - Pipeline by SentoClone International AB, H2 2014 150
Gastric Cancer - Pipeline by Sequella, Inc., H2 2014 151
Gastric Cancer - Pipeline by Siena Biotech S.p.A., H2 2014 152
Gastric Cancer - Pipeline by Supratek Pharma Inc., H2 2014 153
Gastric Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 154
Gastric Cancer - Pipeline by Synthon BV, H2 2014 155
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 156
Gastric Cancer - Pipeline by Tesaro, Inc., H2 2014 157
Gastric Cancer - Pipeline by Vaxon Biotech, H2 2014 158
Gastric Cancer - Pipeline by Zymeworks Inc., H2 2014 159
Assessment by Monotherapy Products, H2 2014 160
Assessment by Combination Products, H2 2014 161
Number of Products by Stage and Target, H2 2014 163
Number of Products by Stage and Mechanism of Action, H2 2014 171
Number of Products by Stage and Route of Administration, H2 2014 177
Number of Products by Stage and Molecule Type, H2 2014 179
Gastric Cancer Therapeutics - Recent Pipeline Updates, H2 2014 464
Gastric Cancer - Dormant Projects, H2 2014 592
Gastric Cancer - Dormant Projects (Contd..1), H2 2014 593
Gastric Cancer - Dormant Projects (Contd..2), H2 2014 594
Gastric Cancer - Dormant Projects (Contd..3), H2 2014 595
Gastric Cancer - Dormant Projects (Contd..4), H2 2014 596
Gastric Cancer - Dormant Projects (Contd..5), H2 2014 597
Gastric Cancer - Dormant Projects (Contd..6), H2 2014 598
Gastric Cancer - Discontinued Products, H2 2014 599
Gastric Cancer - Discontinued Products (Contd..1), H2 2014 600